title: Clinical benchmark for healing of chronic venous ulcers. Venous Ulcer Study Collaborators.
abstract: BACKGROUND
  To determine the results of standardized ulcer treatment regimes and effects of the oral thromboxane A2 antagonist Ifetroban (250 mg daily) on healing of chronic lower-extremity venous stasis ulcers.
  
  
  METHODS
  In a prospective, randomized, double blind, placebo-controlled multicenter study, 165 patients were randomized to Ifetroban (n = 83) versus placebo (n = 82) for a period of 12 weeks. Both groups were treated with sustained graduated compression and hydrocolloid. Ulcer size was measured weekly by tracings and computerized planimetry. A total of 150 patients completed the study.
  
  
  RESULTS
  Complete ulcer healing was achieved after 12 weeks in 55% of patients receiving Ifetroban and in 54% of those taking a placebo with no significant differences; 84% of ulcers in both groups achieved greater than 50% area reduction in size.
  
  
  CONCLUSIONS
  These results are likely to be useful as a benchmark for comparison with other treatment protocols concerning the care of chronic lower-extremity stasis ulcers.
authors.affiliation: Division of Vascular Surgery, Montefiore Medical Center, and the Albert Einstein College of Medicine, New York, New York, USA.
authors.forename: R T
authors.initials: RT
authors.lastname: Lyon
authors.forename: F J
authors.initials: FJ
authors.lastname: Veith
authors.forename: L
authors.initials: L
authors.lastname: Bolton
authors.forename: F
authors.initials: F
authors.lastname: Machado
mesh_terms: D000328:Adult; D000368:Aged; D001458:Bandages; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000008:administration & dosage / Q000627:therapeutic use*; D003102:Colloids / Q000008:administration & dosage; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010080:Oxazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D010919:Placebos; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D013997:Time Factors; D014647:Varicose Ulcer / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D019086:Bridged Bicyclo Compounds, Heterocyclic; D003102:Colloids; D010080:Oxazoles; D010919:Placebos; D010975:Platelet Aggregation Inhibitors; C078904:ifetroban